Company intelligence / Profile preview

Anhui Jiren Pharmaceutical Co., Ltd.

Ownership: Private
Development stage: Commercial

Overview

Anhui Jiren Pharmaceutical has an approved herbal product, ShuFengJieDu Capsule, used for respiratory tract infections in China since 2009. It also has a pending antifungal drug candidate, Iodiconazole, targeting fungal CYP51A1. The company is recognized as a national high-tech enterprise focused on modernizing traditional Chinese medicine and integrating it with pharmaceutical manufacturing. No detailed clinical trial results are publicly available.

Therapeutic areas: Infectious Diseases
Modalities: Herbal medicineSmall molecules/chemical drugs
Industry: Biotech

Drug pipeline

2 assets

Shufeng Jiedu

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Anhui Jiren Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anhui Jiren Pharmaceutical Co., Ltd..